Vamorolone

Catalyst Enters 2025 With Strong Momentum; Reiterates Confidence in Full-Year Outlook Delivers Record Q1 2025 Total Revenues of $141.4 Million, a 43.6% YoY Increase FIRDAPSE® and AGAMREE® Drive Sustained Organic Growth, Underscoring Execution Strength Reaffirms Full-Year 2025 Total Revenue Guidance Provided Earlier This Year of Between $545 Million and $565 Million Strengthens Balance Sheet with Cash and Cash Equivalents of $580.7 Million and No Debt as of March 31, 2025 Conference Call and Webcast to be Held on May 8, 2025 , at 8:30 AM ET CORAL GABLES, Fla. , May 07, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals , Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), today reported financial results for the first quarter of 2025 and provided a business update. "Catalyst's exceptional first quarter performance underscores the continued strength of our commercial strategy and the growing demand for our differentiated therapies," said Richard J. Daly , President and CEO of Catalyst. "Our 43.6% year-over-year total revenue growth for the first quarter of 2025 is a testament to our focused execution and the increasing recognition of the value that our therapies deliver. Looking ahead, we see meaningful opportunities to further establish AGAMREE as a cornerstone therapy in the Duchenne muscular dystrophy (DMD) market and expand FIRDAPSE's clinical utility in Lambert-Eaton myasthenic syndrome (LEMS), addressing a significant unmet need for patients in both markets. We continue to evaluate strategically aligned opportunities to strengthen our portfolio and expand our reach to serve more patients. Building on our momentum, we are confident in our ability to execute our 2025 strategic priorities and drive long-term growth." Financial Highlights _________________________________*For Q1 2024, represents product revenue, net from March 13, 2024 (the date of commercial availability) through the end of the quarter. **Statements made in this press release include non-GAAP financial measures. Such information is provided as additional information and not as an alternative to Catalyst's financial statements presented in accordance with U.S. generally accepted accounting principles ("GAAP"). These non-GAAP financial measures are intended to enhance an overall understanding of Catalyst's current financial performance. Catalyst believes that the non-GAAP financial measures presented in this press release provide investors and prospective investors with an alternative method for assessing Catalyst's operating results in a manner that Catalyst believes is focused on the performance of ongoing operations and provides a more consistent basis for comparison between periods. Non-GAAP financial measures should not be considered in isolation or as a substitute for comparable GAAP accounting. Further, non-GAAP measures of net income used by Catalyst may be different from and not directly comparable to similarly titled measures used by other companies. First Quarter 2025 Financial HighlightsThe Company delivered record first quarter 2025 results, reflecting the continued strength of its commercial execution and the durability of its growth strategy. Total Q1 2025 product revenue, net was $141.4 million , a 43.6% year-over-year increase driven by broad-based demand across the commercial portfolio. FIRDAPSE® Q1 2025 product revenue, net was $83.7 million , a 25.3% year-over-year increase, reflecting continued organic growth and a modest benefit from normalized prescription patterns following temporary disruptions related to the Change Healthcare cybersecurity incident in Q1 2024. AGAMREE® Q1 2025 product revenue, net was $22.0 million , compared to product revenue, net of $1.2 million in 2024 for the period that the product was available after its launch on March 13, 2024 . The results underscore continued growth and increasing prescriber engagement. FYCOMPA® Q1 2025 product revenue, net was $35.6 million , a 17.1% year-over-year increase driven by ongoing demand ahead of anticipated generic competition in the second half of 2025. Year-to-date 2025 Select Business HighlightsCatalyst continued to advance its strategic objectives in the first quarter of 2025, achieving key milestones across intellectual property and regulatory progress. On April 8, 2025 , Catalyst announced that Health Canada accepted the New Drug Submission for AGAMREE with Priority Review. The submission, filed by our sub-licensee in Canada , Kye Pharmaceuticals , has the potential to be approved by year-end 2025, which would position AGAMREE as the first authorized treatment option indicated for patients diagnosed with DMD in Canada . During the first quarter of 2025, the SUMMIT Study advanced with the activation of additional sites and continued progress in patient enrollment, with the goal of providing long-term real-world evidence of the benefits of AGAMREE over other DMD treatments. On January 21, 2025 , FIRDAPSE was launched in Japan by sub-licensee DyDo Pharma for the treatment of LEMS, marking a strategic expansion of the product's footprint and enhancing access for underserved LEMS patient populations in this region. On January 8, 2025 , Catalyst announced a settlement agreement with Teva Pharmaceuticals USA, Inc. , and Teva Pharmaceuticals, Inc. (collectively, "Teva"), resolving the patent litigation initiated by Catalyst and SERB in response to Teva's Abbreviated New Drug Application (ANDA) for a generic version of FIRDAPSE. Under the terms of the agreement, Teva may not market its generic product in the U.S. before February 25, 2035 , subject to certain conditions. However, two remaining ANDA litigations regarding Catalyst’s FIRDAPSE patents continue. 2025 Financial Outlook ReaffirmedThe Company is reaffirming its full-year 2025 revenue outlook, reflecting confidence in its continued commercial execution and portfolio performance. Total revenues, net for 2025 is expected to range between $545 million and $565 million . FIRDAPSE product revenue, net for 2025 is expected to range between $355 million and $360 million . AGAMREE product revenue, net for 2025 is expected to range between $100 million and $110 million . FYCOMPA product revenue, net for 2025 is expected to range between $90 million and $95 million , reflecting the anticipated impact of the loss of market exclusivity for the tablets in May 2025 and the oral suspension in December 2025 . First Quarter 2025 Financial Results Cost of sales: Cost of sales for the first quarter of 2025 was $17.9 million , compared to $12.5 million in the first quarter of 2024. As previously disclosed, royalties and milestone obligations related to AGAMREE are expected to increase if full-year product revenue exceeds $100 million . Royalties for FYCOMPA will commence following the loss of market exclusivity in May 2025 and will be subject to tiered rates based on annual net sales and the timing of generic entry. Milestone obligations are recorded when the obligation is incurred and capitalized over the remaining useful life of the asset. Research and development expenses: Research and development expenses for the first quarter of 2025 were $3.9 million, compared to $2.6 million in the first quarter of 2024. The Company anticipates full-year 2025 research and development expenses to range between $15.0 million and $20.0 million , excluding the impact of any additional acquisitions, reflecting investments in the SUMMIT study and the start of initiatives to investigate the potential for AGAMREE’s label to be expanded in the future. Selling, general, and administrative expenses: Selling, general, and administrative (SG&A) expenses for the first quarter of both 2025 and 2024 were $46.9 million. SG&A expenses are expected to increase modestly over the remainder of the year, reflecting personnel additions during 2024 and the strategic realignment of dedicated commercial teams supporting FIRDAPSE and AGAMREE which became effective at the start of the 2025 second quarter. Amortization of intangible assets: Amortization of intangible assets was $9.3 million for the first quarter of both 2025 and 2024. Operating income: Operating income for the first quarter of 2025 was $63.4 million, compared to $27.1 million in the first quarter of 2024, representing an increase of approximately 133.6%. GAAP net income: GAAP net income for the first quarter of 2025 was $56.7 million ( $0 .47 per basic and $0.45 per diluted share), compared to GAAP net income of $23.3 million ( $0.20 per basic and $0.19 per diluted share) in the first quarter of 2024. Non-GAAP net income: Non-GAAP net income for the first quarter of 2025 was $86.6 million ( $0 .71 per basic and $0.68 per diluted share), compared to non-GAAP net income of $46.8 million ( $0.40 per basic and $0.38 per diluted share) in the first quarter of 2024. Non-GAAP net income for all periods excludes from net income stock-based compensation, depreciation, amortization of intangible assets, and the income tax provision. Tax rate: The Company’s effective income tax rate was 20.4% and 20.0% for the three months ended March 31, 2025 and 2024, respectively. Differences in the effective tax and the statutory federal income tax rate of 21% are driven by state income taxes, fluctuations in the value of investments, and anticipated annual permanent differences offset by equity compensation deductions. Cash and cash equivalents: Cash and cash equivalents were $580.7 million as of March 31, 2025. Our Form 10-Q for the first quarter of 2025, filed with the U.S. Securities and Exchange Commission on May 7, 2025, provides more detailed financial information and analysis of our financial condition and results of operations. The webcast will be accessible under the Investors section on the Company's website at www.catalystpharma.com. A webcast replay will be available on Catalyst's website for at least 30 days following the date of the event. About Catalyst Pharmaceuticals Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence while actively seeking to expand its global commercial footprint through strategic agreements. Catalyst, headquartered in Coral Gables, Fla. , was recognized on the Forbes 2025 list as one of America's Most Successful Mid-Cap Companies and on the 2024 Deloitte Technology Fast 500™ list as one of North America's Fastest-Growing Companies. For more information, please visit Catalyst's website at www.catalystpharma.com. Forward-Looking StatementsThis press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including (i) whether Catalyst's revenue forecasts for 2025 that are included in this press release will prove to be accurate, (ii) whether Catalyst will continue to be profitable and cash flow positive in 2025 and beyond, (iii) whether Catalyst will complete any acquisitions of additional products, and the timing of any such acquisitions, (iv) the impact of the pending Paragraph IV litigation relating to FIRDAPSE if the results of these litigation matters are adverse, and (v) those factors described in Catalyst's Annual Report on Form 10-K for the 2024 fiscal year, Catalyst's Quarterly Report on Form 10-Q for the first quarter of 2025, and its subsequent filings with the U.S. Securities and Exchange Commission ("SEC"), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC , may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date. _________________________________________ (a) exclusive of amortization of intangible assets Source: Catalyst Pharmaceuticals, Inc. Source: Catalyst Pharmaceuticals, Inc.

Pratteln, Switzerland, April 29, 2025 – Santhera Pharmaceuticals (SIX: SANN) today published the invitation to its Annual General Meeting (AGM), which will be held on May 20, 2025, at 10:00 CEST at Haus der Wirtschaft, Hardstrasse 1, 4133 Pratteln, Switzerland. The invitation to the AGM with agenda items and explanations will be sent to registered shareholders by mail and can be viewed on Santhera’s website at www.santhera.com/investors-and-media/investor-toolbox/share-bondholder-meetings Agenda (Overview) Approval of the Annual Report, Annual Financial Statements and the Consolidated Financial Statements 2024Appropriation of the Annual Result and Offset of Deficit Consultative Vote on the Compensation Report 2024Discharge of the Members of the Board of Directors and of the Executive Management from Liability for the Financial Year 2024Conditional Capital for Employee Participations and Amendment to the Articles of IncorporationElection of a new Member & Re-election of two Members of the Board of Directors and of the Chairman of the Board Re-election of the Members of the Nomination & Compensation CommitteeApproval of the Compensation of the Members of the Board of DirectorsApproval of the Compensation of the Members of the Executive Management Re-election of the Statutory AuditorsRe-election of the Independent Proxy About Santhera Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular diseases with high unmet medical need. The Company has an exclusive license from ReveraGen for all indications worldwide to AGAMREE® (vamorolone), a dissociative steroid with novel mode of action, which was investigated in a pivotal study in patients with Duchenne muscular dystrophy (DMD) as an alternative to standard corticosteroids. AGAMREE for the treatment of DMD is approved in the U.S. by the Food and Drug Administration (FDA), in the EU by the European Medicines Agency (EMA), in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA), in China by the National Medical Products Administration (NMPA) and Hong Kong by the Department of Health (DoH). Santhera has out-licensed rights to AGAMREE for North America to Catalyst Pharmaceuticals and for China and certain countries in Southeast Asia to Sperogenix Therapeutics. For further information, please visit www.santhera.com. AGAMREE® is a trademark of Santhera Pharmaceuticals. For further information please contact: Catherine Isted, Chief Financial Officer: IR@santhera.com ICR Healthcare Santhera@icrhealthcare.com Disclaimer / Forward-looking statements This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements. # # # Attachment 250429 Notice of AGM English Final